FDA Listing for Biosimilars: How They Are Evaluated and Approved
Jan, 15 2026
The FDA doesn’t rate biosimilars like products on a scale from 1 to 10. There’s no A, B, or C grade. Instead, it uses a strict, science-driven process to decide if a biosimilar is close enough to its reference biologic to be approved for use in patients. This isn’t like approving a generic pill. Biosimilars are made from living cells-complex proteins that can vary slightly even between batches of the same drug. That’s why the FDA’s approach is far more detailed than what’s used for traditional generics.
How Biosimilars Are Different from Generics
Generics are exact chemical copies of small-molecule drugs. If you take a generic ibuprofen, it’s chemically identical to the brand name. Biosimilars aren’t copies-they’re highly similar versions of large, complex biologic drugs made from living organisms. Think of it like trying to recreate a handmade Swiss watch using the same blueprints, tools, and materials. Even with perfect instructions, tiny differences in craftsmanship can show up. The FDA doesn’t demand perfection. It demands that any differences don’t affect safety or effectiveness.
For a generic drug, the FDA only needs to prove it releases the same active ingredient at the same rate. For a biosimilar, the agency requires hundreds of tests-analytical, preclinical, and clinical-to show the product behaves the same way in the body. This is why biosimilars take longer and cost more to develop than generics. The process isn’t shortcuts; it’s science.
The Step-by-Step FDA Evaluation Process
Getting a biosimilar approved isn’t a single test. It’s a chain of evidence, built layer by layer. The FDA calls this the “totality of evidence” approach. Here’s how it works:
- Analytical Studies: This is the foundation. Developers use advanced tools like mass spectrometry, capillary electrophoresis, and chromatography to compare the biosimilar and reference product at the molecular level. They look at over 200 critical quality attributes-things like protein folding, sugar attachments (glycosylation), and impurity profiles. The goal? At least 95% similarity across most attributes. Some, like charge variants, need 99% alignment. If the data doesn’t show this level of match, the application stops here.
- Animal Studies: The FDA may require toxicity studies in animals, but often waives them if analytical data is strong enough. This step isn’t about proving safety in humans-it’s about spotting red flags early.
- Human Pharmacokinetic (PK) and Pharmacodynamic (PD) Studies: These are small trials in healthy volunteers or patients. They measure how fast the drug enters the bloodstream (PK) and how it affects the body (PD). A two-way crossover design is standard: patients get the reference product, then the biosimilar, or vice versa. Usually, 50-100 people are enrolled. The results must show no clinically meaningful difference in absorption or effect.
- Immunogenicity Assessment: Biologics can trigger immune responses. The FDA requires long-term monitoring-up to a year-to check if the biosimilar causes more or different immune reactions than the reference product. This is critical because immune responses can reduce effectiveness or cause serious side effects.
- Clinical Efficacy Studies: The FDA no longer requires these for every biosimilar. Since September 2024, if analytical and PK/PD data are robust, especially for well-understood proteins, the agency may waive this step. This was a major shift. Before 2024, nearly all biosimilars needed full clinical trials. Now, only complex molecules or those with uncertain mechanisms require them.
This process is longer and more expensive than for generics. Development can take 3-7 years and cost $100-200 million. But the FDA’s goal isn’t to make it easy-it’s to make it safe.
The Purple Book: The Official FDA Listing
If you want to know which biosimilars are approved and what they’re approved for, you check the Purple Book. It’s the FDA’s official database of all biologics-both reference products and their biosimilars. Updated daily since early 2025, it’s searchable online and even has an API for developers and pharmacists.
As of October 2025, the Purple Book lists 387 reference biologics and 43 approved biosimilars. Of those 43, only 17 are designated as “interchangeable.” That’s a higher standard. An interchangeable biosimilar must prove it can be switched with the reference product without increasing risk or reducing effectiveness. It’s not just similar-it’s substitutable. So far, most interchangeable biosimilars are for autoimmune conditions like rheumatoid arthritis and Crohn’s disease.
Each entry includes: the reference product name, approval date, exclusivity period, patent information, and whether it’s interchangeable. This transparency helps pharmacists, doctors, and insurers make informed decisions.
Why the FDA’s Approach Is Stricter Than Europe’s
The European Medicines Agency (EMA) approved its first biosimilar in 2006 and has since approved 118. The FDA approved its first in 2015 and has approved 43. Why the gap? The FDA demands more analytical data. While EMA accepts some clinical studies based on extrapolation from one indication to another, the FDA requires stronger evidence that the biosimilar behaves the same way across all uses.
Dr. Steven Kozlowski, former director of the FDA’s Office of Biotechnology Products, said in a 2023 interview: “The FDA’s analytical requirements are deeper and more comprehensive.” That means longer development times-on average, 3.2 years from IND submission to approval in the U.S., compared to 2.1 years in Europe. But it also means fewer surprises after approval.
Post-market data backs this up. Since 2015, the FDA’s Sentinel Initiative has tracked over 1.2 million patient-years of biosimilar use. Adverse event rates are statistically identical to reference products: 0.8 per 10,000 patients for biosimilars, 0.7 for the originals. No new safety signals have emerged.
Real-World Challenges and Market Gaps
Even with approval, biosimilars don’t always reach patients. Between 2015 and 2025, the FDA approved 43 biosimilars-but only 29 have launched. Why? Patent lawsuits. Drugmakers of reference products often file lawsuits to delay competition. On average, it takes 11.3 months from approval to market launch because of legal battles.
Adoption also varies by disease. In oncology, biosimilars for drugs like rituximab and trastuzumab have captured 65-75% of the market within 18 months. In autoimmune diseases, like those treating adalimumab (Humira), adoption is slower. By Q2 2025, adalimumab biosimilars held only 28% market share, far below the 50% the FDA expected. Prescribers are cautious. Payers sometimes restrict access. Patients don’t always know they’re getting a biosimilar.
Manufacturers also face technical hurdles. The analytical phase alone can cost $120-180 million. Most development teams need 200-300 person-years of work. A single mistake in glycosylation analysis can delay approval by months. The FDA’s 2024 guidance now requires 5-7 orthogonal methods per attribute-up from 3-5-making compliance harder but data more reliable.
What’s Changing in 2025-2027
The FDA is adapting. In June 2025, it updated its guidance to allow indication extrapolation based on analytical data alone-for certain well-characterized proteins. This means a biosimilar approved for one condition (like rheumatoid arthritis) can be used for others (like psoriasis) without additional clinical trials, if the science supports it.
Another big change: AI is being piloted to help review analytical data. By Q1 2026, the FDA will test machine learning tools to detect patterns in mass spectrometry results faster and more accurately. This could cut review times by 30%.
And there’s a push for complex biosimilars. So far, only three applications for antibody-drug conjugates (ADCs) have been submitted. None have been approved. The FDA plans to release specific guidance for these advanced products by Q3 2026.
By 2030, the FDA projects biosimilars will make up 30% of the U.S. biologics market-up from 18% in 2024-and save $250 billion in cumulative costs. That’s a huge win for patients and the system. But the path isn’t smooth. Until prescribers, payers, and patients fully trust biosimilars, their potential won’t be fully realized.
What Patients and Providers Should Know
If you’re prescribed a biosimilar, you’re getting a drug that’s as safe and effective as the original. The FDA doesn’t approve anything less. The only difference might be the price-typically 15-30% lower. You won’t feel different. You won’t notice a change in side effects. The data shows no difference.
Doctors should feel confident prescribing biosimilars. Pharmacists can substitute interchangeable ones without needing a new prescription. Patients should ask questions. If they’re told, “This is cheaper,” they should also ask, “Is it just as safe?” The answer is yes-because the FDA made sure of it.
Are biosimilars the same as generics?
No. Generics are exact chemical copies of small-molecule drugs. Biosimilars are highly similar versions of complex biologic drugs made from living cells. While generics can be chemically identical, biosimilars can have minor differences in structure, but those differences must not affect safety or effectiveness. The FDA’s approval process for biosimilars is far more complex than for generics.
What does "interchangeable" mean for a biosimilar?
An interchangeable biosimilar has met a higher FDA standard. It must prove that switching between it and the reference product won’t increase risk or reduce effectiveness. In many states, pharmacists can substitute an interchangeable biosimilar without the prescriber’s permission-just like they do with generics. Only 17 of the 43 FDA-approved biosimilars have this designation as of October 2025.
Why are so few biosimilars on the market if the FDA has approved 43?
Patent litigation is the biggest barrier. Reference drug manufacturers often sue to delay competition. On average, it takes 11.3 months from FDA approval to market launch. Some biosimilars never launch because legal battles drag on for years. Also, payer restrictions and prescriber hesitation slow adoption, especially in autoimmune diseases.
Is it safe to switch from a reference biologic to a biosimilar?
Yes. The FDA requires extensive data to prove no clinically meaningful differences in safety or effectiveness. Post-market surveillance since 2015 shows adverse event rates for biosimilars are statistically identical to reference products. For interchangeable biosimilars, switching is not just safe-it’s designed to be seamless.
Can biosimilars be used for all the same conditions as the reference product?
Sometimes, yes. The FDA allows "extrapolation"-approving a biosimilar for multiple conditions based on data from one indication-if the science supports it. Since June 2025, this is allowed for well-characterized proteins if analytical and PK/PD data are strong. But for complex molecules or unclear mechanisms, clinical data for each indication is still required.
What’s Next for Biosimilars in the U.S.
The future hinges on three things: faster approvals, better education, and fewer legal barriers. The FDA’s roadmap includes AI-assisted reviews, clearer guidance for complex products, and a formal framework for combination product biosimilars by 2027. If these changes stick, approvals could rise from 3-5 per year to 7-9 by 2027.
But the real win will come when patients and doctors stop seeing biosimilars as "second-choice" drugs. They’re not. They’re scientifically validated alternatives that bring down costs without compromising care. The FDA’s process ensures that. Now, the system needs to catch up.
Kasey Summerer
January 16, 2026 AT 13:20kanchan tiwari
January 17, 2026 AT 06:44john Mccoskey
January 17, 2026 AT 13:52Ryan Hutchison
January 19, 2026 AT 09:00Stephen Tulloch
January 19, 2026 AT 14:20Joie Cregin
January 20, 2026 AT 01:43Melodie Lesesne
January 21, 2026 AT 06:28Corey Chrisinger
January 22, 2026 AT 05:48Bianca Leonhardt
January 23, 2026 AT 02:24Travis Craw
January 23, 2026 AT 06:24Nicholas Gabriel
January 24, 2026 AT 06:25